GLOBAL GENETIC TESTING MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • GLOBAL GENETIC TESTING MARKET FORECAST 2019-2027

GLOBAL GENETIC TESTING MARKET FORECAST 2019-2027

The global genetic testing market is anticipated to grow at a CAGR of 10.59% between 2019 and 2027 to generate revenue of $20,507 million by 2027. Genetic testing can divulge alterations or changes in the genes that may incur disease or illness. The important drivers that are increasing the growth of the global genetic testing market are growing usage of diagnosing genetic disorders and the rise in the incidence of genetic diseases. Genetic disorders are the major reasons for the chronic disease.

GLOBAL GENETIC TESTING MARKET  FORECAST 2019-2027

Request free sample

The global genetic testing market is anticipated to grow at a CAGR of 10.59% between 2019 and 2027 to generate revenue of $20,507 million by 2027. Genetic testing can divulge alterations or changes in the genes that may incur disease or illness. The genetic testing market is primarily driven by the following factors:

  • Growing usage of diagnosing genetic disorders
  • The rise in incidence of genetic diseases
  • Minimal health risk associated with genetic testing
  • The surge in RNA pipeline tests
  • Advances in genetic testing for cancer
  • Growing aging population

The important drivers that are increasing the growth of the global genetic testing market are growing usage of diagnosing genetic disorders and the rise in the incidence of genetic diseases. Genetic disorders are the major reasons for the chronic disease. Genetic testing provides technologies that are helpful in the early detection of these genetic disorders and ensure their treatment and prevention. According to the World Health Organization, the global prevalence of all single-gene diseases at birth is approximately 10 per 1,000 births.

The surge in genetic diseases is escalating market growth. Genes play an important role in the development of diseases, such as dementia and Alzheimer’s. Cancer is a disease with one of the highest incidence rates. Breast, lung, and prostate cancers are some of the most common forms. Cystic fibrosis (CF) is an inherited disease, which majorly affects the lungs, pancreas, and sweat glands. Sickle cell anemia is a hereditary condition, which results in the creation of an irregular type of hemoglobin called hemoglobin S (Hgb S or Hb S). Duchenne muscular dystrophy and Becker muscular dystrophy occurs by mutations in the dystrophinencoding DMD gene. Thalassemia is a group of inherited blood disorders, which can be passed from parents to their children, and affect the amount and type of hemoglobin that the body produces. Confirmatory and diagnostic testing and prenatal and predictive genetic tests are available for Huntington’s disease. Various predictive tests are used in other diseases such as cardiovascular, rheumatoid arthritis, gout, etc. There are many genetic diseases that are prevalent among people.

Inaccuracies in results and reimbursement issues are the major factors hindering the genetic testing market. Genetic testing offers many important opportunities for the assessment for risks in the genes and its diagnosis, but some of the genetic testing does not recognize all of the possible gene mutation which can be caused in particular condition or they just give limited predictive value. Reimbursement decisions about genetic testing are difficult to make due to the lack of general data about the finances involved. The cost of assessing new technologies for genetic testing is also difficult.

The global genetic testing market segments include technology, type, and disease.

Technology is segmented into:

  • Cytogenetic Testing
  • Biochemical Testing
  • Molecular Testing

Type is segmented into:

  • Carrier Testing
  • Diagnostic Testing
  • Newborn Screening
  • Predictive and Presymptomatic Testing
  • Prenatal Testing
  • Other Types

Disease is segmented into:

  • Alzheimer’s Disease
  • Cancer
  • Thalassemia
  • Sickle Cell Anemia
  • Rare Diseases
  • Cystic Fibrosis
  • Duchenne Muscular Dystrophy
  • Huntington’s disease
  • Other Diseases

This report covers the present market conditions and the growth prospects of the global genetic testing market for 2019-2027 and considered the revenue generated through the sales of genetic testing for technology, type as well as a disease to calculate the market size by considering 2018 as the base year.

Geographically, the global genetic testing market has been segregated on the basis of four chief regions, which comprise:

  • North America – The United States & Canada
  • Asia-Pacific – China, India, Japan, Australia, South Korea & Rest of Asia Pacific
  • Europe – The United Kingdom, France, Germany, Italy, Spain & Rest of Europe
  • Rest of World – Latin America and the Middle East and Africa

The genetic testing market in North America is expected to hold the largest share by 2027 possibilities of presence of key players such as Genetech and oxford biomedical in the biotechnology industry, who is investing largely for the improvement of the new technology which can be used in the growth of new testing techniques and advancement of the existing ones. North America comprised a market share of approx. 47% in 2018. There is an increasing demand for personalized genetic testing services in North America, due to the rise in the prevalence of chronic disorders and genetic disorders.

On the other hand, the Asia-Pacific market is anticipated to the fastest-growing region for the Genetic testing market. The genetic testing market in Asia Pacific is expected to grow at a rapid pace driven by the growth of molecular biology applications and technological breakthroughs. Child health, cancer risk studies, and infectious disease testing are the most common forms of genetic testing in APAC.

The genetic testing market is segmented based on types which are sub-divided into carrier testing, diagnostic testing, newborn screening, predictive and presymptomatic testing, prenatal testing and other types as well as based on technology which is sub-divided into cytogenetic testing, biochemical testing and molecular testing. Carrier testing is a type of genetic testing used to determine whether a person is a carrier for specific autosomal recessive diseases. Diagnostic testing is performed to rule out or confirm the chromosomal or genetic abnormalities associated with a person. Newborn screening is done just after the baby is born in order to test the genetic disorders so that it can be treated in early life stage. Cytogenetic testing involves the examination of the chromosomes to identify structural abnormalities. Molecular genetic testing is the study of single genes or short lengths of DNA.

The major market players in the global genetic testing market are:

  • Qiagen N.V.
  • Oxford Biodynamics Limited
  • Luminex Corporation
  • Danahar (Cepheid)
  • Roche Diagnostics Corporation

Company profiles covers the analysis of important players. Qiagen was incorporated in 1986 and is headquartered in KJ Venlo, the Netherlands. Qiagen achieved a healthy market position in the Sample Assay and Technologies market and focuses on building a strong global position in the field of healthcare. The company markets over 500 core products that are distributed in various combinations. ROCHE diagnostics corporation Provides solutions, instrument systems, tests, software, and services that support clinical decision making in a variety of indication fields, including virology, oncology, inflammatory, cardiovascular, and infectious diseases.

Key findings of the global genetic testing market:

  • Molecular testing is the fastest-growing genetic testing technology
  • Cancer market holds the largest market share in terms of disease
  • Diagnostic testing is the widely used genetic testing type
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • MOLECULAR TESTING IS THE FASTEST GROWING GENETIC TESTING TECHNOLOGY
      • CANCER MARKET HOLDS THE LARGEST MARKET SHARE IN TERMS OF DISEASE
      • DIAGNOSTIC TESTING IS THE WIDELY USED GENETIC TESTING TYPE
  1. MARKET DYNAMICS
    • MARKET SCOPE & DEFINITION
    • MARKET DRIVER
      • GROWING USAGE OF DIAGNOSING GENETIC DISORDERS
      • RISE IN INCIDENCE OF GENETIC DISEASES
      • MINIMAL HEALTH RISK ASSOCIATED WITH GENETIC TESTING
      • SURGE IN RNA PIPELINE TESTS
      • ADVANCES IN GENETIC TESTING FOR CANCER
      • GROWING AGING POPULATION
    • MARKET RESTRAINTS
      • INACCURACIES IN RESULTS
      • REIMBURSEMENT ISSUES
      • PSYCHOLOGICAL IMPACT
      • LACK OF PRECISION IN TESTING
    • MARKET OPPORTUNITIES
      • GENETIC COUNSELLING
      • RISING CLINICAL APPLICATION FOR GENETIC TESTING
      • INNOVATION IN THE TREATMENT AND DIAGNOSTIC
    • MARKET CHALLENGES
      • HIGH COST OF MEDICATION AND TESTS
      • HIGH COST OF RAW MATERIAL
      • RISE IN GENETIC DISCRIMINATION
  1. MARKET BY TECHNOLOGY
    • CYTOGENETIC TESTING
    • BIOCHEMICAL TESTING
    • MOLECULAR TESTING
  2. MARKET BY TYPE
    • CARRIER TESTING
    • DIAGNOSTIC TESTING
    • NEWBORN SCREENING
    • PREDICTIVE AND PRESYMPTOMATIC TESTING
    • PRENATAL TESTING
    • OTHER TYPES
  3. MARKET BY DISEASE
    • ALZHEIMER’S DISEASE
    • CANCER
    • CYSTIC FIBROSIS
    • SICKLE CELL ANEMIA
    • DUCHENNE MUSCULAR DYSTROPHY
    • THALASSEMIA
    • HUNTINGTON’S DISEASE
    • RARE DISEASES
    • OTHER DISEASES
  4. KEY ANALYTICS
    • PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF RIVALRY
    • KEY BUYING CRITERIA
      • COST
      • ACCURACY
      • AVAILABILITY
      • RELIABILITY
    • MARKET TRENDS
      • HEALTH INFORMATION IS RISING SIGNIFICANTLY
      • INCREASING DEMAND FOR PERSONALIZED MEDICINE
      • NEW PRODUCT LAUNCHES
      • TECHNOLOGY ADVANCEMENTS
    • PESTEL ANALYSIS
    • OPPORTUNITY MATRIX
  5. GEOGRAPHIC ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF APAC
    • REST OF WORLD (ROW)
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA (MEA)
  1. COMPANY PROFILING
    • 23ANDME
    • ABBOTT LABORATORIES
    • BIO-RAD LABORATORIES, INC.
    • DANAHAR CORPORATION (CEPHEID)
    • DAAN DIAGNOSTICS LTD.
    • GENENTECH, INC.
    • GENOMICTREE, INC.
    • HTG MOLECULAR DIAGNOSTICS, INC.
    • ILLUMINA, INC.
    • INTEGRAGEN S.A
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • LUMINEX CORPORATION
    • MYRIAD GENETICS, INC.
    • NATERA, INC.
    • OXFORD BIODYNAMICS LIMITED
    • PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    • PERKINELMER, INC.
    • QIAGEN N.V.
    • ROCHE DIAGNOSTICS CORPORATION

 

LIST OF TABLES

TABLE 1        GLOBAL GENETIC TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 2        COST OF SELECTED DRUGS IN CANCER THERAPY

TABLE 3        GLOBAL GENETIC TESTING MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)

TABLE 4        GLOBAL CYTOGENETIC TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 5        GLOBAL BIOCHEMICAL TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 6        GLOBAL MOLECULAR TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 7        GLOBAL GENETIC TESTING MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE 8        GLOBAL CARRIER TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 9        GLOBAL DIAGNOSTIC TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 10      GLOBAL NEWBORN SCREENING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 11      GLOBAL PREDICTIVE AND PRESYMPTOMATIC TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 12      GLOBAL PRENATAL TESTING MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 13      GLOBAL OTHER TYPES MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 14      GLOBAL GENETIC TESTING MARKET BY DISEASE 2019-2027 ($ MILLION)

TABLE 15      GLOBAL ALZHEIMER’S DISEASE MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 16      GLOBAL CANCER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 17      GLOBAL CYSTIC FIBROSIS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 18      GLOBAL SICKLE CELL ANEMIA MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 19      GLOBAL DUCHENNE MUSCULAR DYSTROPHY MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 20      GLOBAL THALASSEMIA MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 21      GLOBAL HUNTINGTON’S DISEASE MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 22      GLOBAL RARE DISEASES MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 23      GLOBAL OTHER DISEASES MARKET BY REGION 2019-2027 ($ MILLION)

TABLE 24      NORTH AMERICA GENETIC TESTING MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE 25      INCIDENCE RATES OF LEADING CHRONIC DISORDERS IN EUROPE 2016 (%)

TABLE 26      EUROPE GENETIC TESTING MARKET 2019-2027

TABLE 27      ASIA PACIFIC GLOBAL GENETIC TESTING MARKET BY COUNTRIES 2019-2027 ($ MILLION)

TABLE 28      REST OF WORLD GENETIC TESTING MARKET BY REGION 2019-2027 ($ MILLION)

 

LIST OF FIGURES

FIGURE 1      GLOBAL GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 2      SAMPLES TYPES IN GENETIC TESTING

FIGURE 3      GLOBAL GERIATRIC POPULATION (65+) 2015 & 2020 (MILLION)

FIGURE 4      PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050

FIGURE 5      LAB AUTOMATION TECHNOLOGY BENEFITS GENETIC DIAGNOSTIC INDUSTRIES

FIGURE 6      GLOBAL GENETIC TESTING MARKET SHARE BY TECHNOLOGY 2018 & 2027 (%)

FIGURE 7      GLOBAL GENETIC TESTING MARKET BY CYTOGENETIC TESTING 2019-2027 ($ MILLION)

FIGURE 8      GLOBAL GENETIC TESTING MARKET BY BIOCHEMICAL TESTING 2019-2027 ($ MILLION)

FIGURE 9      GLOBAL GENETIC TESTING MARKET BY MOLECULAR TESTING 2019-2027 ($ MILLION)

FIGURE 10   GLOBAL GENETIC TESTING MARKET SHARE BY TYPE 2018 & 2027 (%)

FIGURE 11   GLOBAL GENETIC TESTING MARKET BY CARRIER TESTING 2019-2027 ($ MILLION)

FIGURE 12   GLOBAL GENETIC TESTING MARKET BY DIAGNOSTIC TESTING 2019-2027 ($ MILLION)

FIGURE 13   GLOBAL GENETIC TESTING MARKET BY NEWBORN SCREENING 2019-2027 ($ MILLION)

FIGURE 14   GLOBAL GENETIC TESTING MARKET BY PREDICTIVE AND PRESYMPTOMATIC TESTING 2019-2027 ($ MILLION)

FIGURE 15   GLOBAL GENETIC TESTING MARKET BY PRENATAL TESTING 2019-2027 ($ MILLION)

FIGURE 16   GLOBAL GENETIC TESTING MARKET BY OTHER TYPES 2019-2027 ($ MILLION)

FIGURE 17   GLOBAL GENETIC TESTING MARKET SHARE BY DISEASE 2018 & 2027 (%)

FIGURE 18   GLOBAL GENETIC TESTING MARKET BY ALZHEIMER’S DISEASE 2019-2027 ($ MILLION)

FIGURE 19   GLOBAL GENETIC TESTING MARKET BY CANCER 2019-2027 ($ MILLION)

FIGURE 20   GLOBAL GENETIC TESTING MARKET BY CYSTIC FIBROSIS 2019-2027 ($ MILLION)

FIGURE 21   GLOBAL GENETIC TESTING MARKET BY SICKLE CELL ANEMIA 2019-2027 ($ MILLION)

FIGURE 22   GLOBAL GENETIC TESTING MARKET BY DUCHENNE MUSCULAR DYSTROPHY 2019-2027 ($ MILLION)

FIGURE 23   GLOBAL GENETIC TESTING MARKET BY THALASSEMIA 2019-2027 ($ MILLION)

FIGURE 24   GLOBAL GENETIC TESTING MARKET BY HUNTINGTON’S DISEASE 2019-2027 ($ MILLION)

FIGURE 25   GLOBAL GENETIC TESTING MARKET BY RARE DISEASES 2019-2027 ($ MILLION)

FIGURE 26   GLOBAL GENETIC TESTING MARKET BY OTHER DISEASES 2019-2027 ($ MILLION)

FIGURE 27   PORTER’S FIVE FORCE MODEL

FIGURE 28   HEALTHCARE EXPENDITURE IN THE U.S. 2014 & 2025 (% OF GDP)

FIGURE 29   THE UNITED STATES GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 30   CANADA GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 31   THE UNITED KINGDOM GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 32   FRANCE GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 33   GERMANY GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 34   SPAIN GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 35   ITALY GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 36   REST OF EUROPE GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 37   PERCENTAGE OF AGING POPULATION IN ASIA 2010 AND 2050

FIGURE 38   INDIA GENETIC TESTING MARKET 2019-2027($ MILLION)

FIGURE 39   CHINA GENETIC TESTING MARKET 2019-2027 ($MILLION)

FIGURE 40   JAPAN GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 41   AUSTRALIA GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 42   SOUTH KOREA GENETIC TESTING MARKET 2019-2027($ MILLION)

FIGURE 43   REST OF APAC GENETIC TESTING MARKET 2019-2027($ MILLION)

FIGURE 44   LATIN AMERICA GENETIC TESTING MARKET 2019-2027 ($ MILLION)

FIGURE 45   MIDDLE EAST AND AFRICA GENETIC TESTING MARKET 2019-2027 ($ MILLION)

  1. MARKET BY TECHNOLOGY
    • CYTOGENETIC TESTING
    • BIOCHEMICAL TESTING
    • MOLECULAR TESTING
  2. MARKET BY TYPE
    • CARRIER TESTING
    • DIAGNOSTIC TESTING
    • NEWBORN SCREENING
    • PREDICTIVE AND PRESYMPTOMATIC TESTING
    • PRENATAL TESTING
    • OTHER TYPES
  3. MARKET BY DISEASE
    • ALZHEIMER’S DISEASE
    • CANCER
    • CYSTIC FIBROSIS
    • SICKLE CELL ANEMIA
    • DUCHENNE MUSCULAR DYSTROPHY
    • THALASSEMIA
    • HUNTINGTON’S DISEASE
    • RARE DISEASES
    • OTHER DISEASES
  4. GEOGRAPHIC ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE
    • ASIA PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF APAC
    • REST OF WORLD (ROW)
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA (MEA)

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now